2019 - a momentous year for the NHS
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how the Long Term Plan has been driving transformation in the NHS this year
PharmaTimes -
December 2019
2019 has been quite the year for UK pharma and healthcare, with these sectors experiencing unprecedented challenge, change and uncertainty. As the year’s last issue of PharmaTimes goes to press, and a general election looms ahead, the outlook for 2020 is still anyone’s guess (but more on that in the January/February edition!).
In our review of the year series, the team at Wilmington (p16) describes the momentous transformation of the NHS propelled by the introduction of a Long Term Plan. On page 30, Alantra’s Tom Cowap highlights a busy year for pharma M&A activity, with the stage set for more big deals to close early 2020. Also, Ana Nicholls offers an insightful look at the Brexit saga and its impact on pharma and healthcare (p33).
Our Business Insight with AbbVie on page 26 highlights the burden of rheumatoid arthritis and the continued pursuit of disease remission. Elsewhere, John Pinching gives his take on pharma sales forces past, present and future (p23).
There’s also a fascinating interview with Gilead’s Hillary Hutton-Squire (39), and on page 20 we celebrate the winners of the PharmaTimes Communications Team of the Year, Marketer of the Year and Sales Awards – congratulations to all who made it through to the finals! On that note, PharmaTimes is also delighted to announce the launch of the 10th Clinical Researcher of the Year 2020 – The Americas competition, see www.pharmatimes.com/ competitions for more information.
I hope enjoy the issue!
December 2019 - magazine highlights
Going for gold
Who emerged victorious at this year’s Marketer of the Year, Communications Team of the Year and Sales competitions?
Bag to the future
For decades intrepid pharma sales forces navigated the road network of Great Britain with little more than paper, pen and personality – hoping that one day the tools of their trade would mirror the cutting-edge science of the products they showcased. In recent years, the digital era has truly arrived, but as 2020 looms, big challenges still remain
Unlocking value
How can 2020 be the year that R&D really delivers value, people get real about data, and pharma starts to develop even better medicines?
2019 – the return of the mega deal?
Globally mega deals continue to abound, domestically the mid-market and PE have been the core drivers of activity
The year of no Brexit (again)
Political uncertainty became endemic during 2019, despite a lot of government planning
Raising the bar
A 2019 review has shown that the current system for detecting cancer is failing to reach its potential. Fujifilm’s Adrian Waller says we need a more tech-enabled and patient-centred approach
A clearer picture
Marni Hall and Nicola Stanislaus look at the growing role of real-world evidence
Smart People: Hilary Hutton-Squire
PharmaTimes talks to Hilary Hutton-Squire, vice president and general manager of Gilead Sciences in the UK and Ireland, about the importance of valuing medicines in the right way
